MedTrace Logo

Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence

NCT01984177 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2016-08-09

No results posted yet for this study

Summary

This study will, in a sample of cocaine-dependent and healthy control subjects, administer corticorelin and compare dopamine release between groups. Dopamine release will be measured using PET neuroimaging with the radiotracer \[11C\]-(+)-PHNO.

Conditions

  • Cocaine-Related Disorders
  • Cocaine Addiction
  • Substance-Related Disorders

Interventions

DRUG

Corticotropin-Releasing Hormone

Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Isabelle Boileau, PhD · Centre for Addiction and Mental Health, Research Imaging Centre

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01984177 on ClinicalTrials.gov